A Superior Sunscreen Ingredient Is Finally Coming to the U.S.

The U.S. Food and Drug Administration (FDA) has approved bemotrizinol as the first new active sunscreen ingredient in the country since the 1990s. This chemical filter, already used in Europe and Asia, provides superior broad-spectrum protection against both UVA and UVB radiation while remaining photostable—unlike avobenzone, which degrades in sunlight. Bemotrizinol also shows minimal skin absorption and no estrogenic effects in lab studies, addressing consumer concerns about hormone disruption linked to ingredients like oxybenzone. Dermatologists describe bemotrizinol as a significant advancement in sun protection. Jane Yoo, MD, MPP, a board-certified dermatologist at Icahn School of Medicine at Mount Sinai, called the approval a ‘historic day’ for U.S. public health, noting the regulatory gap had long limited access to advanced sunscreen ingredients. Lauren A. Fine, MD, of Fine Dermatology in Chicago, emphasized its effectiveness against UVA radiation, which causes photoaging and precancerous cells. The ingredient is safe for adults and children over six months old, with no significant skin irritation reported. Unlike many chemical filters, bemotrizinol remains stable without additional stabilizers, making it a more reliable option for daily use. Early commercial products containing bemotrizinol are expected to reach U.S. shelves by August 2024, according to Yoo. The approval follows years of advocacy by dermatologists and regulatory delays unique to the FDA’s sunscreen evaluation process. Bemotrizinol’s low systemic absorption also eases concerns for individuals with sensitive skin or those wary of potential hormone-disrupting effects from other sunscreen chemicals. While further human studies are needed, current data suggests it offers a safer, more effective alternative to existing filters.